auristatin

01/01/2017 - "This study confirms pHLIP-monomethyl auristatin conjugates as possible new therapeutic options for cancer treatment and supports their further development."
01/15/2016 - "The aim of the study is to investigate combination regimens of auristatin-based ADCs in preclinical models of cancer. "
07/26/2023 - "Click Chemistry Selectively Activates an Auristatin Protodrug with either Intratumoral or Systemic Tumor-Targeting Agents."
01/01/2022 - "In patient-derived xenograft (PDX), cell-line xenograft (CLX), and mouse syngeneic tumor models, EDB-ADC, conjugated to auristatin Aur0101 through site-specific technology, demonstrated potent antitumor growth inhibition. "
01/01/2022 - "In vivo, ADCT-601 had potent and durable antitumor activity in a wide variety of human cancer xenograft mouse models, including patient-derived xenograft models with heterogeneous AXL expression where ADCT-601 antitumor activity was markedly superior to an auristatin-based comparator ADC. "

03/02/2018 - "Targeted Delivery of Auristatin-Modified Toxins to Pancreatic Cancer Using Aptamers."
12/27/2022 - "In this study, we generated the antibody drug conjugate (ADC) by conjugating HzMUC1 with monomethyl auristatin (MMAE), and examined the efficacy of HzMUC1-MMAE against the MUC1-positive pancreatic cancer in vitro and in vivo. "
12/25/2023 - "In this study, we developed a novel antibody-drug conjugate (ADC)-the auristatin-based hSD5-vedotin specifically targeting EphA2 in pancreatic cancer cells. "
12/25/2023 - "An auristatin-based antibody-drug conjugate targeting EphA2 in pancreatic cancer treatment."
10/01/2019 - "An auristatin-based antibody-drug conjugate targeting HER3 enhances the radiation response in pancreatic cancer."

04/01/2023 - "We developed a novel humanized antibody that specifically binds MUC1 expressed in breast cancer cells and conjugated a humanized MUC1 (HzMUC1) antibody to monomethyl auristatin (MMAE). "
06/09/2021 - "In both in vitro and in vivo assays, ABBV-176 exhibits potent cytotoxicity against multiple cell line and patient-derived xenograft breast tumor models, including triple negative and low PRLR expressing models insensitive to monomethyl auristatin (MMAE) based PRLR ADCs. "
01/15/2016 - "Breast cancer cells treated with auristatin analogue or 5T4-ADC were profiled by total- and phospho-proteomics. "
12/08/2021 - "Furthermore, an antibody-drug conjugate (ADC) was generated by conjugating HzMUC1 with monomethyl auristatin (MMAE), and the efficacy of HzMUC1-MMAE on the MUC1-positive HER2+ breast cancer in vitro and in 'Xenograft' model was tested. "

10/01/2018 - "EV20-mediated delivery of cytotoxic auristatin MMAF exhibits potent therapeutic efficacy in cutaneous melanoma."
06/01/2006 - "Potent cytotoxicity of an auristatin-containing antibody-drug conjugate targeting melanoma cells expressing melanotransferrin/p97."
02/15/2006 - "CR011, a fully human monoclonal antibody-auristatin E conjugate, for the treatment of melanoma."

07/21/2020 - "When loaded with the chemotherapy monomethyl auristatin (MMAE), the PVX nanocarrier enables effective delivery of MMAE to human B lymphoma cells in a NHL mouse model leading to inhibition of lymphoma growth in vivo and improved survival. "
04/30/2009 - "Potent antitumor activity of the anti-CD19 auristatin antibody drug conjugate hBU12-vcMMAE against rituximab-sensitive and -resistant lymphomas."